Genetic prodrug activation therapy

被引:26
|
作者
Rigg, A
Sikora, K
机构
[1] ICRF Molecular Oncology Unit, Imperial College of Medicine, Hammersmith Hospital, London W12 0NN, Du Cane Road
来源
MOLECULAR MEDICINE TODAY | 1997年 / 3卷 / 08期
关键词
D O I
10.1016/S1357-4310(97)01082-4
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Genetic prodrug activation therapy shows promise as a therapeutic option for the treatment of cancer as well as a variety of other diseases. it involves the insertion of a gene encoding a drug-metabolizing enzyme into cells and the systemic administration of a prodrug. The prodrug is converted to a cytotoxic agent by the action of the expressed enzyme. To ensure that the enzyme is only expressed in the targeted subset of cells, the transcriptional apparatus of a gene that is unique to this subset is used to regulate the gene encoding the drug-metabolizing enzyme. As with all types of gene therapy, one of the major obstacles to successful clinical treatment is the development of safe and effective gene delivery systems.
引用
收藏
页码:359 / 366
页数:8
相关论文
共 50 条
  • [31] Prodrug activation by Cryptosporidium thymidine kinase
    Sun X.E.
    Sharling L.
    Muthalagi M.
    Mudeppa D.G.
    Pankiewicz K.W.
    Felczak K.
    Rathod P.K.
    Mead J.
    Striepen B.
    Hedstrom L.
    Journal of Biological Chemistry, 2010, 285 (21) : 15916 - 15922
  • [32] PRODRUG ACTIVATION VIA CATALYTIC ANTIBODIES
    MIYASHITA, H
    KARAKI, Y
    KIKUCHI, M
    FUJII, I
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (11) : 5337 - 5340
  • [33] Enzyme prodrug therapy of cancer
    Blakey, D
    EXPERT OPINION ON THERAPEUTIC PATENTS, 1997, 7 (09) : 965 - 977
  • [34] Bioorthogonal chemistry for prodrug activation in vivo
    Fu, Qunfeng
    Shen, Siyong
    Sun, Pengwei
    Gu, Zhi
    Bai, Yifei
    Wang, Xianglin
    Liu, Zhibo
    CHEMICAL SOCIETY REVIEWS, 2023, 52 (22) : 7737 - 7772
  • [35] Solving the Prodrug Design and Activation Puzzle
    Hilfinger, John
    MOLECULAR PHARMACEUTICS, 2013, 10 (02) : 429 - 429
  • [36] Electrodrugs: an electrochemical prodrug activation strategy
    Norman, Daniel J.
    Gonzalez-Fernandez, Eva
    Clavadetscher, Jessica
    Tucker, Lulu
    Staderini, Matteo
    Mount, Andrew R.
    Murray, Alan F.
    Bradley, Mark
    CHEMICAL COMMUNICATIONS, 2018, 54 (66) : 9242 - 9245
  • [37] Prodrug strategies in cancer therapy
    Denny, WA
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2001, 36 (7-8) : 577 - 595
  • [38] ANTIBODY-CATALYZED PRODRUG ACTIVATION
    CAMPBELL, DA
    GONG, B
    KOCHERSPERGER, LM
    YONKOVICH, S
    GALLOP, MA
    SCHULTZ, PG
    JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1994, 116 (05) : 2165 - 2166
  • [39] Oxidative and reductive prodrug activation strategies
    Hu, Longqin
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 243
  • [40] Nanozyme-prodrug therapy
    Zelikin, Alexander
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2019, 258